×
About 13,535 results

ALLMedicine™ Congestive Heart Failure Center

Research & Reviews  3,947 results

Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tol...
https://doi.org/10.1253/circj.CJ-21-0430
Circulation Journal : Official Journal of the Japanese Ci... Sato N, Uno S et. al.

Sep 14th, 2021 - Tolvaptan is an orally administered aquaretic drug indicated for patients with congestive heart failure (CHF) to remove excess fluid. OPC-61815, a prodrug of tolvaptan with improved water solubility, is considered suitable for intravenous (IV) adm...

Clinical and hemodynamic outcomes of the Dor procedure in adults with ischemic cardiomy...
https://doi.org/10.1111/jocs.15968
Journal of Cardiac Surgery; Fatehi Hassanabad A, Wiebe K et. al.

Sep 9th, 2021 - Ischemic cardiomyopathy continues to be a major contributor to congestive heart failure, which places a significant burden on our healthcare system. Improving medications and different coronary revascularization strategies are the mainstays in the...

Premature ventricular complexes and development of heart failure in a community-based p...
https://doi.org/10.1136/heartjnl-2021-319473
Heart (British Cardiac Society); Limpitikul WB, Dewland TA et. al.

Sep 9th, 2021 - A higher premature ventricular complex (PVC) frequency is associated with incident congestive heart failure (CHF) and death. While certain PVC characteristics may contribute to that risk, the current literature stems from patients in medical setti...

"She knows me best": a qualitative study of patient and caregiver views on the role of ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421240
BMC Family Practice; Griffiths S, Stephen G et. al.

Sep 8th, 2021 - Patients with chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are at high-risk of readmission after hospital discharge. There is conflicting evidence however on whether timely follow-up with a primary care provider ...

Prognosticators of All-Cause Mortality in Patients With Heart Failure With Preserved Ej...
https://doi.org/10.1016/j.amjcard.2021.07.044
The American Journal of Cardiology; Lopuszynski JB, Downing AJ et. al.

Sep 2nd, 2021 - Heart failure with preserved ejection fraction (HFpEF) represents ∼50% of all cases of congestive heart failure (CHF) with prevalence expected to increase with aging of the population. We performed an observational study of all patients admitted t...

see more →

Guidelines  6 results

Appropriate Use of Point-of-Care Ultrasonography in Patients With Acute Dyspnea in Emer...
https://doi.org/10.7326/M20-7844
Annals of Internal Medicine; Qaseem A, Etxeandia-Ikobaltzeta I et. al.

Apr 27th, 2021 - The American College of Physicians (ACP) developed this guideline to provide clinical recommendations on the appropriate use of point-of-care ultrasonography (POCUS) in patients with acute dyspnea in emergency department (ED) or inpatient settings...

Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Scienc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903778
Circulation Rimm EB, Appel LJ et. al.

May 19th, 2018 - Since the 2002 American Heart Association scientific statement "Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease," evidence from observational and experimental studies and from randomized controlled trials continues to e...

The vascular access in the elderly: a position statement of the Vascular Access Working...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429362
Journal of Nephrology; Lomonte C, Forneris G et. al.

Jan 19th, 2016 - The incident hemodialysis (HD) population is aging, and the elderly group is the one with the most rapid increase. In this context it is important to define the factors associated with outcomes in elderly patients. The high prevalence of comorbidi...

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-po...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076031
Journal of Clinical Oncology : Official Journal of the Am... Giordano SH, Temin S et. al.

May 7th, 2014 - To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. The American Society of Clinical Oncology conven...

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stro...
https://doi.org/10.1016/j.cjca.2010.11.007
The Canadian Journal of Cardiology; Cairns JA, Connolly S et. al.

Feb 19th, 2011 - The stroke rate in atrial fibrillation is 4.5% per year, with death or permanent disability in over half. The risk of stroke varies from under 1% to over 20% per year, related to the risk factors of congestive heart failure, hypertension, age, dia...

see more →

Drugs  759 results see all →

Clinicaltrials.gov  9 results

Mechanically Optimizing Cardiac Preload in Heart Failure Patients
https://clinicaltrials.gov/ct2/show/NCT04338503

Dec 29th, 2020 - The purpose of the current study is to determine if partial balloon occlusion of the inferior vena cava can optimize cardiac pre-load and subsequently pulmonary pressures and cardiac output as a novel method to unload pulmonary edema and other sym...

GENETIC BASIS of LEFT VENTRICULAR APICAL HYPOPLASIA
https://clinicaltrials.gov/ct2/show/NCT04339582

Apr 10th, 2020 - Brief summary Left ventricular apical hypoplasia (LVAH) is a rare cardiomyopathy characterized by a spherical, truncated LV with some degree of systolic dysfunction, an elongated, normally functioning right ventricle that wraps around the distal l...

Atrial Flow Regulator in Heart Failure
https://clinicaltrials.gov/ct2/show/NCT04334694

Apr 6th, 2020 - The aim of the study is to assess invasive and non-invasive parameters that may predict clinical improvement in patients with congestive heart failure after implantation of Occlutech® Atrial flow regulator (AFR) device.

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
https://clinicaltrials.gov/ct2/show/NCT01324453

Jun 5th, 2019 - Single center study involving 140 patients randomized to Post Conditioning + Percutaneous coronary intervention (PCI) versus routine PCI during their ST-Elevation Myocardial Infarction (STEMI, Heart Attack) presentation. The Post Conditioning prot...

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01310010

Sep 29th, 2015 - Participants - inclusion criteria Adult patients ≥ 18 years. Diagnostic confirmation of de novo Ph+ ALL. Patients in first/second CR (assessed by cytology, karyotyping and/or FISH) at transplantation. Patients with sustained hematologic and cytoge...

see more →

News  690 results

Balixafortide Plus Eribulin Fails to Improve ORR in Advanced HER2-Negative Breast Cancer
https://www.onclive.com/view/balixafortide-plus-eribulin-fails-to-improve-orr-in-advanced-her2-negative-breast-cancer

Jun 30th, 2021 - The combination of balixafortide (POL6326) and eribulin (Halaven) did not significantly improve objective response rate (ORR) over eribulin alone in the treatment of patients with HER2-negative, locally recurrent or metastatic breast cancer, missi...

The Next Chapter in RCC Recontextualizes Treatment Considerations
https://www.onclive.com/view/the-next-chapter-in-rcc-recontextualizes-treatment-considerations

Jun 15th, 2021 - Renal cell carcinoma (RCC) is one of the top 10 most common cancers, although incidence rates have been stable over the past decade. It is more common in men than women and rates are higher among African American, American Indian, and Alaska Nativ...

A Farmer With Diffuse Pruritus and a Suntan That Won't Fade
https://reference.medscape.com/viewarticle/952272

Jun 8th, 2021 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...

Ponatinib/Blinatumomab Combo Represents Promising Chemo-Free, HSCT-Sparing Treatment for Ph+ ALL
https://www.onclive.com/view/ponatinib-blinatumomab-combo-represents-promising-chemo-free-hsct-sparing-treatment-for-ph-all

Jun 4th, 2021 - The efficacy demonstrated with combination of ponatinib (Iclusig) and blinatumomab (Blincyto) represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant (HSCT)–sparing treatment for patients with Philadelphia chromosom...

Experts Point to Better Ways to Handle Hospital Conflicts
https://www.medscape.com/viewarticle/952083

May 28th, 2021 - Imagine a hospitalist, part of a group with 35 hospitalists, is in her second year of practice and is caring for a 55-year-old woman with a history of congestive heart failure and cirrhosis from hepatitis C due to heroin use. The patient was hospi...

see more →

Patient Education  3 results see all →